Roche continues regulatory run with acute stroke expansion for heart attack drug

TNKase is the first stroke drug to win FDA approval in nearly three decades.
The FDA signed off Monday on the use of Roche’s thrombolytic drug TNKase to treat acute ischemic stroke in adult patients.

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for stroke in almost 30 years. Roche and Genentech also own Activase, the only other acute ischemic stroke (AIS) drug approved by the FDA.